LGD 1331

Drug Profile

LGD 1331

Latest Information Update: 18 Sep 2006

Price : $50

At a glance

  • Originator Ligand Pharmaceuticals
  • Class Antiandrogens; Antineoplastics
  • Mechanism of Action Testosterone congener inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Acne; Alopecia; Benign prostatic hyperplasia; Hirsutism; Polycystic ovary syndrome; Prostate cancer

Most Recent Events

  • 18 Sep 2006 Discontinued - Preclinical for Benign prostatic hyperplasia in USA (unspecified route)
  • 18 Sep 2006 Discontinued - Preclinical for Prostate cancer in USA (unspecified route)
  • 18 Sep 2006 Discontinued - Preclinical for Acne in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top